Drugs / Vidofludimus
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 27 trials · 1 met primary · 2 missed | ||||||
| Phase 2 | NCT05054140 | Sep 2021 → Jan 2025 | multiple sclerosis | Immunic AG | Unknown | No outcome recorded |
| Phase 2 | NCT04516915 | Jun 2020 → May 2022 | COVID-19 | University Hospitals Coventry and Warwickshire NHS Trust | Completed | No outcome recorded |
| Phase 2 | NCT03722576 | Jun 2019 → Jun 2020 | primary sclerosing cholangitis | Elizabeth Carey | Completed | No outcome recorded |
| Phase 2 | NCT03846219 | Jan 2019 → Apr 2020 overdue | relapsing-remitting multiple sclerosis | Immunic AG | Active not recruiting | Met primary |
| Phase 2 | NCT03341962 | Mar 2018 → Nov 2022 | ulcerative colitis | Immunic AG | Terminated | Missed primary |
| Phase 2 | NCT01010581 | Nov 2009 → Apr 2011 | rheumatoid arthritis | 4SC AG | Completed | Missed primary |
| Phase 2 | NCT00820365 | Mar 2009 → Oct 2010 | inflammatory bowel disease | 4SC AG | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04379271 | Jun 2020 → Jan 2021 | COVID-19 | Immunic AG | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05201638 | Jan 2022 → Nov 2026 expected | relapsing-remitting multiple sclerosis | Immunic AG | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05134441 | Nov 2021 → Nov 2026 expected | multiple sclerosis | Immunic AG | Active not recruiting | No outcome recorded |
Press releases naming this drug 2 releases
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vidofludimus | “Vidofludimus (SC12267) is a novel oral immunomodulator inhibiting dihydroorotate dehydrogenase (DHODH) and the expression of proinflammatory cytokines including interleukin-17...” PMID 23078909 ↗ Oct 2012 |
| Known as | 4SC-101 | “SC12267 (4SC-101)” NCT01010581 ↗ |
| Known as | IMU-838 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04516915 ↗ |
| Known as | NSC-717824 | ChEMBL registry synonym — accepted as the source's own label CHEMBL197194 ↗ |
| Known as | SC12267 | “Vidofludimus (SC12267) is a novel oral immunomodulator inhibiting dihydroorotate dehydrogenase (DHODH) and the expression of proinflammatory cytokines including interleukin-17...” PMID 23078909 ↗ Oct 2012 |
| Known as | vidofludimus calcium | “IMU-838 (vidofludimus calcium) when delivered in combination with an antiviral therapy (oseltamivir)” NCT04516915 ↗1“IMU-838 (vidofludimus calcium), a small molecule inhibitor of dihydroorotate dehydrogenase (DHODH)” NCT03846219 ↗ |
| Action | Inhibit | “Vidofludimus (SC12267) is a novel oral immunomodulator inhibiting dihydroorotate dehydrogenase (DHODH)” PMID 23078909 ↗ Oct 2012 |
| Modality | Small molecule | “Small Molecule Inhibitor” NCT03722576 ↗ |
| Route | Oral | “once daily 35mg oral dose of vidofludimus” PMID 23078909 ↗ Oct 2012 |
| Target | DHODH | “inhibitor of dihydroorotate dehydrogenase (DHODH)” NCT03846219 ↗ |